Loading clinical trials...
Loading clinical trials...
A Two Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of the Combined Use of Once Daily 10mg Dapagliflozin and Once Weekly 1.0mg Semaglutide in Kidney Transplant Recipients
Conditions
Interventions
Dapagliflozin 10 MG
Semaglutide, 1.0 mg/mL
Locations
1
Canada
Toronto General Hospital
Toronto, Ontario, Canada
Start Date
October 24, 2023
Primary Completion Date
October 1, 2025
Completion Date
October 1, 2025
Last Updated
January 31, 2025
NCT05702398
NCT06806670
NCT02555566
NCT04965935
NCT02424227
NCT01517984
Lead Sponsor
University Health Network, Toronto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions